



HCC- UK Annual Conference
'Accelerating improvements for patients with HCC'
Bridgewater Hall, Manchester

Thursday 27st March 2025 – Basic and Translational Science Day

11:00-12:00 Registration – arrivals, refreshments and networking

Session 1 – Advancements in integrative AI (Chair: Dr Matthew Hoare)

12:00-12:05 *Welcome and Introduction* – Professor Tom Bird, Consultant Hepatologist, University of Glasgow

12:05-12:30 *Integrative computation in cancer biology* - Crispin Miller, CRUK Scotland Institute

12:30-13:00 *AI in liver disease* – Professor Jakob Kather, Technical University Dresden

13:00-13:15 *Multimic analysis demonstrates hepatocyte SOX9 loss exacerbates fibrosis and HCC development* - Dr Elliot Jokl, University of Manchester

13:30–14:30 Lunch and poster viewing

Session 2 – Keynote session (Chair: Tom Bird)

14:30 - 14:45 *Novel multiomics biomarker signature derived from blood circulating hepatocyte-extracellular vesicles for the early detection of HCC* - Dr Tomas Dias, Mursla Bio

14.45 - 15:00 *The translational repressor, eIF4A2, promotes extracellular matrix deposition to accelerate hepatocellular carcinoma initiation* – Dr Madeleine Moore, CRUK Scotland Institute

15:00 - 15:15 *Fine needle aspirates capture immunotherapy biomarkers and targets compartmentalised within hepatocellular carcinoma tumours* – Dr Gloryanne Aidoo-Micah, University College London

15:15 - 15:30 *Harnessing enclysis to control regulatory T cell frequencies in the liver tumour microenvironment* - Dr Zania Stamataki, University of Birmingham

15:30-16:05 *Genetics of adenoma and HCC progression* - Professor Jessica Zucman Rossi, University Paris Descartes

16:05–16:45 Tea and Coffee



Session 3 – Tumour evolution in metabolic liver disease (Chair: Shish Shetty)

16:45 – 16:55 *Hepatic cell evolution in premalignant MASLD* – Professor Ram DasGupta, University of Glasgow

16:55 - 17:20 *Metabolic heterogeneity in HCC: searching for new targets of treatment* – Professor Patricia Aspichueta, Universidad del País Vasco, Spain.

17:20 – 17:35 *Epigenetic regulation of liver endothelial cells as a novel target to boost immunotherapy efficacy in hepatocellular cancer* - Mr Saad Rehman

19:00 Evening meal (arrival 19:00, dinner 19:15)

Friday 28th March 2025 - Clinical Day

8:00-9:00 Registration and coffee

8:20-8:50 Sponsored Symposium

9:00-9:05 Welcome and Introduction to the Clinical Day – Dr Richard Hubner, Consultant medical oncologist

Session 4 – Radiotherapy and clinical innovations (Chair: Tim Meyer)

9.05 – 9.35 *New therapies: Proton Beam therapy* - Professor Maria Hawkins and Dr Ganesh Radhakrishna

9.35 – 9:50 *Identification of novel phosphoproteomic signatures predictive of response to atezolizumab and bevacizumab (AB) in a UK cohort of patients with advanced hepatocellular carcinoma (aHCC)* - Dr Christina Karampera, King's College Hospital

9:50 – 10:05 *Clinical predictors of overall survival after transarterial radioembolisation (TARE) for hepatocellular carcinoma (HCC): a retrospective analysis* - Dr Saur Hajiev, Cambridge Liver Unit

10:05 -10:20 *SHiNE-UK: A national evaluation of hepatocellular carcinoma surveillance, routes to diagnosis and treatment utilisation* - Dr Christopher Mysko, University of Manchester

10:20 – 10:35 *A retrospective analysis of hepatocellular carcinoma patients receiving first line atezolizumab/bevacizumab versus lenvatinib at the Royal Free Hospital between 2017 and 2024* - Dr Alexa Childs



10:35-10:50 *Title tbc* - Pamela Healy, Chief Executive British Liver Trust

10:50-11:50 Coffee, posters and exhibition

11:00-11:30 Sponsored Symposium - AstraZeneca

Session 5 – Early stage disease (Chair: Abid Suddle)

11.50 – 12.15 *Live Donor Liver transplantation* – Professor Krish Menon, Transplant Oncology

12.15 – 12.35 *Evaluation and optimisation of portal hypertension for patients with HCC* Dhiraj Tripathi, Birmingham

12:35-13.10 *The role of neoadjuvant immunotherapy in liver transplantation and liver resection for HCC* – Dr David Pinato

13:10-14:20 Lunch, posters and exhibition

13:45-14:15 Sponsored Symposium

Session 6 – Decision making in the MDT (Chair: Aileen Marshall)

14:15 – 15:15 HCC MDT – Interactive Cases - Diagnostic difficulties in Hepatocellular carcinoma

Cases

1. Dr Abid Suddle - Consultant Hepatologist, Kings College, London
2. Dr Anna Paterson, Consultant Histopathologist, Cambridge University Hospitals.
3. Dr Aileen Marshall & Professor Tim Meyer - Royal Free London

MDT panel

Kelly Farrell - Clinical Nurse Specialist, The Christie NHS Foundation Trust, Manchester

Dr Ian Rowe - Associate Professor & Honorary Consultant Hepatologist, University of Leeds, Leeds

Dr Alexa Childs - Postdoctoral clinical research fellow and honorary consultant in oncology, Royal Free Hospital, London

Dr Anna Paterson, Consultant Histopathologist, Cambridge University Hospitals.

Mr Jack Martin – University of Cambridge

Dr Umberto Pisano - Interventional Radiology & Interventional Oncology Consultant, NHS Greater Glasgow and Clyde

Session- 7 New frontiers in HCC (Chair: Richard Hubner)

15:15-15:45 *Systemic therapy combined with locoregional therapy – state of the art* -Dr Alexa Childs

15:45-16:15 *Metabolic associated steatotic liver disease and HCC* - Professor Helen Reeves, Newcastle



16:15-16:25 Conclusion/Farewell/Prize giving

BASL PARTNERS



SILVER SPONSORS



EXHIBITION SPONSORS

